Management

The UNION team and advisors account for more than 10 drug approvals.

 

Dr. Kim Domela Kjøller, Chief Executive Officer

Kim Domela Kjøller has been the CEO of UNION since January 2021 and brings more than 20 years of experience from various senior positions in pharma, including the last 10 years in dermatology.

Before UNION, Kim was Head of R&D at LEO Pharma.

Kim also held senior positions in both Strategic Marketing, Medical Affairs, Global Development and as General Manager in Sanofi, Lundbeck, Sanofi Pasteur MSD. His past experience covers both corporate and affiliate positions.

Kim is an MD from Copenhagen University and has authored and co-authored over 35 scientific publications, and given presentation at both scientific and pharmaceutical marketing meetings globally.

 

Dr. Rasmus Toft-Kehler

Rasmus Toft-Kehler is the Co-Founder and board member of multiple biotech companies in the fields of microbiome research, immunology, and antibiotic resistance. Prior to entering the biotech sector, Rasmus worked in leading investment banks and in management consulting, and acted as board member of a family-owned enterprise that was sold in 2005.

Rasmus is the inventor of over 5 patents and has published research in leading entrepreneurship and scientific journals such as Journal of Business Venturing and Nature Reviews Microbiology.

Rasmus holds a Ph.D. in entrepreneurship from Copenhagen Business School with research stays at New York University and University of Cambridge as well as Harvard Business School.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.

 

Dr. Morten Sommer, Chief Scientific Officer

Morten Sommer is the Co-Founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.Ds and Post-Doctorial researchers working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents/patent applications and author of scientific papers in journals such as Science, Cell and Nature. Morten was named among the Top 10 under 40 in Genetic Engineering and Biotechnology News list of biopharma research and business executives.

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

 

Dr. Philippe Andres, Medical Lead, Dermatology

Philippe Andres is a French national with over 20 years of experience as dermatologist in the pharma industry, most recently as a member of the executive team at Galderma/Nestlé Skin Health. He has a wealth of experience in encompassing early and late stage developments, scientific communication and medical affairs.

During his career, Philippe has been involved in developing and launching multiple approved products, including topicals calcitriol (Vectical®) and adapalene (Differin®), submitted more than 100 patents and has published numerous scientific papers.

Philippe is an M.D. and Board Certified Dermatologist from Nantes University, France.

 

Dr. Günter Ditzinger, Chief Technology Officer

Günter Ditzinger, Ph.D. has more than 30 years of pharmaceutical innovation experience spanning early development to product launch at Sanofi and subsequently Novartis. Before joining UNION in 2020, Günter was Chief Technology Officer at Basilea Pharmaceutica, where he was responsible for pharmaceutical, chemical and analytical development as well as the commercial supply chain at the global level. Günter has played vital roles in the successful development and commercial launch of multiple marketed products: Toctino® in chronic hand eczema, Zevtera® in bacterial infections, and Cresemba® in systemic fungal Infections.

Günter is a Registered Pharmacist, and holds a Ph.D. in Pharmaceutical Technology from Goethe University in Frankfurt/Main, Germany.

 

Morten Boesen, Chief Financial Officer

Morten Boesen joined Union in 2018 as Chief Financial Officer. Prior to Union, Morten has worked with EQT, the largest private equity fund in the Nordics, first as an Investment Manager and subsequently as an executive director in EQT-owned retail company Flying Tiger Copenhagen, where he held responsibility for strategy, business development as well as global commercial and supply chain operations. Earlier in his career, Morten worked as a management consultant at McKinsey & Company, in the M&A advisory of Nordea Bank and in the finance department of Novozymes, the world leader in industrial biotech.

Morten holds a M.Sc. in Finance and Accounting from Copenhagen Business School and studied at New York University’s Stern School of Business and Tsinghua University’s School of Economics and Management.

 

Dr. Umar Hayat, VP of CMC and Supply Chain

Umar Hayat, Ph.D. has more than 20 years of experience in pharmaceutical development, manufacturing and supply chain. He has held senior level positions at Relypsa (acquired by Galenica for $1.5bn), Anacor (acquired by Pfizer for $5.2bn) and Transcept Pharmaceuticals (merged with Paratek). Umar has played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis.

Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

 

Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Lutz Wevelsiep, Ph.D. has more than 25 years’ experience in international regulatory affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. Lutz has prepared and managed interactions with all health authorities including the  FDA, EMA and EU national agencies.

Prior to UNION, Lutz spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes the successful European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®).

Lutz holds a Ph.D. and Postdoc in Chemistry from the Max-Planck Institute in Germany.

 

Mads Jellingsø, VP, Commercial and Medical Affairs

Mads Jellingsø has broad market access experience from Novo Nordisk A/S where he was part of building new functions for real world evidence generation and for innovative contracting. In these teams Mads was driving Novo Nordisk’s global efforts to initiate partnerships with payers and providers around evidence generation and developing new financial and outcomes-based approaches to secure access for products in hemophilia, diabetes and obesity. Prior to specializing in market access, Mads has worked within the off-shoring and legal affairs department at Novo Nordisk and also has experience in management consulting at McKinsey & Company and in banking at Nordea Markets.

Mads holds a M.Sc. in Economics from University of Copenhagen.